Brian Mueller
Known title: EVP, Chief Financial OfficerCIK: 0001514980
Associated companies
Transaction History
| BMRN | ▼ Sell | Tax Withholding | 2,117 | $119K | 3/17/2026 | View on chart |
| BMRN | ▲ Buy | Grant | 18,740 | $0 | 3/16/2026 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 9,945 | $582K | 3/13/2026 | View on chart |
| BMRN | ▲ Buy | Grant | 6,683 | $0 | 2/25/2026 | View on chart |
| BMRN | ▲ Buy | Grant | 7,230 | $0 | 2/25/2026 | View on chart |
| BMRN | ▲ Buy | Grant | 2,569 | $0 | 2/25/2026 | View on chart |
| BMRN | ▲ Buy | Grant | 16,640 | $0 | 3/17/2025 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 18,497 | $1.3M | 3/14/2025 | View on chart |
| BMRN | ▲ Buy | Grant | 11,040 | $0 | 2/25/2025 | View on chart |
| BMRN | ▲ Buy | Grant | 9,660 | $0 | 2/25/2025 | View on chart |
| BMRN | ▲ Buy | Grant | 9,367 | $0 | 2/25/2025 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 588 | $48K | 6/28/2024 | View on chart |
| BMRN | ▲ Buy | Option Exercise | 5,000 | $316K | 5/30/2024 | View on chart |
| BMRN | ▼ Sell | Open Market | 5,000 | $376K | 5/30/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 300 | $21K | 4/30/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 11,400 | $0 | 3/15/2024 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 20,789 | $1.7M | 3/15/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 20,220 | $0 | 2/27/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 8,802 | $0 | 2/27/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 6,103 | $0 | 2/27/2024 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 4,602 | $409K | 6/29/2023 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 4,602 | $409K | 6/29/2023 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 576 | $51K | 6/29/2023 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 3,973 | $371K | 3/16/2023 | View on chart |
| BMRN | ▲ Buy | Grant | 9,630 | $0 | 3/15/2023 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 2,708 | $238K | 3/15/2023 | View on chart |
| BMRN | ▲ Buy | Grant | 1,250 | $0 | 2/28/2023 | View on chart |
| BMRN | ▲ Buy | Grant | 12,660 | $0 | 2/28/2023 | View on chart |
| BMRN | ▲ Buy | Grant | 10,980 | $0 | 2/28/2023 | View on chart |
| BMRN | ▼ Sell | Open Market | 2,500 | $286K | 1/13/2023 | View on chart |
| BMRN | ▲ Buy | Option Exercise | 2,500 | $158K | 1/13/2023 | View on chart |
| BMRN | ▼ Sell | Open Market | 2,500 | $269K | 12/13/2022 | View on chart |
| BMRN | ▲ Buy | Option Exercise | 2,500 | $158K | 12/13/2022 | View on chart |
| BMRN | ▼ Sell | Open Market | 1,101 | $115K | 12/2/2022 | View on chart |
| BMRN | ▲ Buy | Option Exercise | 2,139 | $145K | 12/2/2022 | View on chart |
| BMRN | ▲ Buy | Option Exercise | 3,761 | $255K | 12/2/2022 | View on chart |
| BMRN | ▼ Sell | Open Market | 3,761 | $393K | 12/2/2022 | View on chart |
| BMRN | ▼ Sell | Open Market | 2,139 | $224K | 12/2/2022 | View on chart |
| BMRN | ▼ Sell | Open Market | 934 | $89K | 11/23/2022 | View on chart |
| BMRN | ▼ Sell | Open Market | 945 | $94K | 11/23/2022 | View on chart |
| BMRN | ▲ Buy | Option Exercise | 3,500 | $237K | 11/23/2022 | View on chart |
| BMRN | ▼ Sell | Open Market | 3,500 | $348K | 11/23/2022 | View on chart |
| BMRN | ▲ Buy | Option Exercise | 3,500 | $237K | 8/5/2022 | View on chart |
| BMRN | ▼ Sell | Open Market | 3,500 | $331K | 8/5/2022 | View on chart |
| BMRN | ▼ Sell | Open Market | 7,337 | $657K | 7/8/2022 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 576 | $48K | 6/29/2022 | View on chart |
| BMRN | ▲ Buy | Option Exercise | 2,038 | $76K | 5/4/2022 | View on chart |
| BMRN | ▼ Sell | Open Market | 2,038 | $172K | 5/4/2022 | View on chart |
| BMRN | ▲ Buy | Option Exercise | 9,762 | $366K | 5/4/2022 | View on chart |
| BMRN | ▼ Sell | Open Market | 9,762 | $825K | 5/4/2022 | View on chart |
| BMRN | ▲ Buy | Grant | 340 | $21K | 4/29/2022 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 582 | $47K | 3/16/2022 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 1,868 | $146K | 3/15/2022 | View on chart |
| BMRN | ▲ Buy | Grant | 11,040 | $0 | 3/15/2022 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 1,072 | $94K | 2/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
BioMarin Reports Phase 3 Pompe Data, Expands AI Partnership
BioMarin presented phase‑3 results for its Pompe disease therapy POMBILITI® combined with OPFOLDA® at the World Muscle Society Congress, reporting sustained efficacy and no new safety signals. The company also announced a partnership with Profluent to use AI for designing enzyme therapies, and a license agreement with Ascendis Pharma that includes royalties on future sales. These developments highlight BioMarin’s focus on expanding its therapeutic pipeline and leveraging technology partnerships.
BioMarin Reports Phase 3 Pompe Data, Expands AI Partnership. BioMarin presented phase‑3 results for its Pompe disease therapy POMBILITI® combined with OPFOLDA® at the World Muscle Society Congress, reporting sustained efficacy and no new safety signals. The company also announced a partnership with Profluent to use AI for designing enzyme therapies, and a license agreement with Ascendis Pharma that includes royalties on future sales. These developments highlight BioMarin’s focus on expanding its therapeutic pipeline and leveraging technology partnerships.